{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:17:09Z","timestamp":1794359829433,"version":"4.9.0"},"reference-count":60,"publisher":"Informa UK Limited","issue":"9","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"NF Network Research Program"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2025,9,2]]},"DOI":"10.1080\/13543784.2025.2558656","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T10:58:28Z","timestamp":1757588308000},"page":"665-673","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["Mirdametinib, an FDA-Approved MEK1\/2 inhibitor for adult and pediatric NF1-associated plexiform neurofibromas"],"prefix":"10.1080","volume":"34","author":[{"given":"Gorkem","family":"Oztosun","sequence":"first","affiliation":[{"name":"Washington University of Medicine","place":["St. Louis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Washington University of Medicine","place":["St. Louis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1719-0771","authenticated-orcid":false,"given":"Angela C.","family":"Hirbe","sequence":"additional","affiliation":[{"name":"Washington University of Medicine","place":["St. Louis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"e_1_3_5_3_1","unstructured":"Friedman JM Mirzaa GM Adam MP et al. Neurofibromatosis 1. In: Adam M Feldman J editors. GeneReviews\u00ae. 1998. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1109\/"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.4"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02911-2"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2018.28"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00368"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-02156-y"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells9112365"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3911"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.049362"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-021-01170-5"},{"key":"e_1_3_5_13_1","unstructured":"Plexiform neurofibromas in NF type 1. [cited 2025 Aug 12]. Available from: ctf.org"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2011.08.051"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0786"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes11030287"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.146351"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2008-011"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy067"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac146"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.01.038"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.JTO.0000391372.94376.37"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1039\/d3md00145h"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10996-y"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.10"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-5032"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03361-4"},{"key":"e_1_3_5_28_1","unstructured":"AstraZeneca Pharmaceuticals LP: KoselugoTM (selumetinib) capsules for oral use. Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2024 [cited 2025 Aug 12]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/213756s004lbl.pdf)"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph15080956"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa222.619"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912735"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03361-4"},{"key":"e_1_3_5_33_1","unstructured":"Mirdametinib NCI drug dictionary. [cited 2025 Aug 12]. Available from: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-drug\/def\/mirdametinib"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2013.10.001"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae064.017"},{"key":"e_1_3_5_36_1","unstructured":"Mirdametinib NCI formulary. [cited 2025 Aug 12]. Availeble from: https:\/\/dctd.cancer.gov\/drug-discovery-development\/reagents-materials\/formulary\/about\/agents\/mirdametinib"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2807"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3722"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI168227"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.122.001431"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1883"},{"key":"e_1_3_5_42_1","unstructured":"Mirdametinib compound summary. [cited 2025 Aug 12]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/pd0325901"},{"key":"e_1_3_5_43_1","unstructured":"Mirdametinib Inxight Drugs information. [cited 2025 Aug 12]. Available from: https:\/\/drugs.ncats.io\/drug\/86K0J5AK6M"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0231"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1593\/neo.09398"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0672"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31052"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab047"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02220"},{"key":"e_1_3_5_50_1","unstructured":"Mirdametinib general drug information. [cited 2025 Aug 12]. Available from: gomekli.com"},{"key":"e_1_3_5_51_1","unstructured":"Mirdametinib drug label information. [cited 2025 Aug 12. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=4c41bf90-5fa7-4935-a95c-e047ea6bbf8e"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1883"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac209.900"},{"key":"e_1_3_5_54_1","unstructured":"Mirdametinib prescribing information. [cited 2025 Aug 12]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219379Orig1s000lbl.pdf"},{"key":"e_1_3_5_55_1","unstructured":"CTNI-20. Addressing skin adverse events during mirdametinib treatment in NF1-PN: expert guidance on MEK inhibitor-associated skin AEs. [cited 2025 Aug 12]. Available from: https:\/\/www.ajmc.com\/formulary\/nf1pn\/Hirbe%20SNO%202024%20Derm%20AE%20Poster.pdf"},{"key":"e_1_3_5_56_1","unstructured":"Esmo guidelines (reactive management of maculopapular rash induced by multikinase inhibitor treatment). [cited 2025 Aug 12]. Available from: oncologypro.esmo.org"},{"key":"e_1_3_5_57_1","unstructured":"Esmo guidelines (What healthcare professionals should do to treat side effects of multikinase inhibitor treatment). [cited 2025 Aug 12]. Available from: oncologypro\/esmo.org"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.21.2241"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0706547"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae014"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01034"},{"key":"e_1_3_5_62_1","unstructured":"Fda approves mirdametinib for adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection. [cited 2025 Aug 12]. Available from: fda.gov"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2025.2558656","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T10:33:09Z","timestamp":1763375589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2025.2558656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,2]]}},"alternative-id":["10.1080\/13543784.2025.2558656"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2025.2558656","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-04-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}